9
Sep 2026
New AI model forecasts glucose changes in type 1 diabetes patients
Diabetes is one of the most common chronic diseases, affecting around 66 million adults in Europe - a figure projected to rise to more than 72 million by 2050.
Stay Informed!
9
Sep 2026
New AI model forecasts glucose changes in type 1 diabetes patients
Diabetes is one of the most common chronic diseases, affecting around 66 million adults in Europe - a figure projected to rise to more than 72 million by 2050.
9
Sep 2026
New AI method tracks immune responses without known antibody databases
A research team comprising Associate Professor FUNAKOSHI Yohei, Associate Professor YAKUSHIJIN Kimikazu, Professor MINAMI Hironobu, and Associate Professor OHJI Goh of Kobe University, together with graduate student MASUDA Genki, then-graduate student IIZUMI Shunsuke, Associate Professor OHUE Masahito, and colleagues at the Institute of Science Tokyo, has developed a new analysis method, LM-QASAS.
9
Sep 2026
Johns Hopkins researchers identify human resistin as a key driver of inflammation
Researchers at Johns Hopkins Medicine have uncovered a critical biological mechanism that helps explain how inflammation is triggered and sustained in a wide range of diseases-highlighting a promising avenue for future therapeutic development.
9
Sep 2026
Is stroke risk higher after a cancer diagnosis?
New research indicates that people with invasive cancer face an elevated risk of experiencing a stroke, especially in the first few months after diagnosis and especially if they have certain types of cancer.
9
Sep 2026
EpilepsyGTx and Viralgen collaborate to advance AAV gene therapy program for epilepsy ahead of first-in-human trial
EpilepsyGTx, a biotechnology company developing gene therapies for refractory epilepsy, and Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (AAV) gene therapies, today announced a partnership to support production of EpilepsyGTx's lead investigational gene therapy program targeting patients with focal refractory epilepsy (FRE), EPY201, ahead of first-in-human clinical trials.
9
Sep 2026
Study uncovers cellular mechanisms behind long-lasting antibody responses
A team led by investigators from the University of Osaka uncovers cellular mechanisms that favor long-lived antibody responses, providing insights that may help researchers design vaccines that provide longer-lasting protection against infection.
9
Sep 2026
AlphaGenome Atlas maps billions of genetic changes with AI
The human genome contains approximately 3 billion DNA letters, creating more than 9 billion possible single-letter changes.
9
Sep 2026
Non-nutritive sweeteners may aid sugar reduction without affecting weight or health
The review, led by Eva Marija Čad of the University of Ljubljana and Wageningen University & Research, alongside Professor Graham Finlayson of the University of Leeds and colleagues from other institutions in the Netherlands, Denmark, Spain and Belgium, was developed in connection with a 2025 webinar series hosted by the Institute for the Advancement of Food and Nutrition Sciences (IAFNS).
9
Sep 2026
Eppendorf launches new refrigerated Centrifuge 5811 R
Eppendorf, a leading international life science company that develops, manufactures, and distributes instruments, consumables, and services for use in laboratories around the world, today announced the launch of the Centrifuge 5811 R, a refrigerated, multipurpose benchtop centrifuge designed to support a wide range of laboratory workflows. It builds on the proven performance and versatility of the Centrifuge 5810 R.
